Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/onco.13768 http://scihub22266oqcxt.onion/10.1002/onco.13768 33783099!8100539!33783099     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncologist 2021 ; 26 (5): e898-e901 Nephropedia Template TP {{tp|p=33783099|t=2021. Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors |pdf=|usr=}}{{33783099}} gab.com Text Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors JO: Oncologist http://www.kidney.de/pget.php?&tw=1&pmid=33783099 #FOAvip OBJECTIVE: The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). MATERIALS AND METHODS: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020. RESULTS: The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility. CONCLUSION: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic. Twit Text FOAVip Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors ????Oncologist http://www.kidney.de/pget.php?&tw=1&pmid=33783099 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33783099 #FOAvip English Wikipedia <ref>{{Cite pmid|33783099}}</ref> Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors #MMPMID33783099 Klebanov N; Pahalyants V; Murphy WS; Theodosakis N; Zubiri L; Klevens RM; Kwatra SG; Lilly E; Reynolds KL; Semenov YR Oncologist 2021[May]; 26 (5): e898-e901 PMID33783099show ga OBJECTIVE: The aim of this study was to determine the rate of coronavirus disease-19 (COVID-19) among patients with cancer treated with immune checkpoint inhibitors (ICIs). MATERIALS AND METHODS: This was a retrospective study of 1,545 patients with cancer treated with ICIs between July 1, 2019, and February 29, 2020, and 20,418 age-, sex-, and cancer category-matched controls in a large referral hospital system. Confirmed COVID-19 case and mortality data were obtained with Massachusetts Department of Public Health from March 1 through June 19, 2020. RESULTS: The mean age was 66.6 years, and 41.9% were female. There were 22 (1.4%) and 213 (1.0%) COVID-19 cases in the ICI and control groups, respectively. When adjusting for demographics, medical comorbidities, and local infection rates, ICIs did not increase COVID-19 susceptibility. CONCLUSION: ICIs did not increase the rate of COVID-19. This information may assist patients and their oncologists in decision-making surrounding cancer treatment during this pandemic. |*COVID-19[MESH] |*Neoplasms/drug therapy[MESH] |Aged[MESH] |Female[MESH] |Humans[MESH] |Immune Checkpoint Inhibitors[MESH] |Male[MESH] |Massachusetts[MESH] |Retrospective Studies[MESH]Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint I(epmc).pdf DeepDyve Pubget Overpricing